Literature DB >> 36255635

Monitoring Changes in Intracellular Reactive Oxygen Species Levels in Response to Histone Deacetylase Inhibitors.

Al-Hassan M Mustafa1,2, Ramy Ashry3,4, Oliver H Krämer3.   

Abstract

Reactive oxygen species (ROS) are induced by several chemotherapeutics. In this protocol, we describe a flow cytometry-based method for the analysis of the intracellular levels of ROS in vital leukemic cells in response to the histone deacetylase inhibitor vorinostat. This measurement of ROS using the cell-permeable dye CM-H2DCFDA indicates intracellular oxidative stress.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Flow cytometry; HDACi; Leukemia; ROS

Mesh：

Substances：

Year:  2023        PMID： 36255635     DOI： 10.1007/978-1-0716-2788-4_22

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  14 in total

1.  Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.

Authors:  Nilsa Rivera-Del Valle; Tiewei Cheng; Mary E Irwin; Hayley Donnella; Melissa M Singh; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-08       Impact factor: 3.333

2.  c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer.

Authors:  Angela Nebbioso; Vincenzo Carafa; Mariarosaria Conte; Francesco Paolo Tambaro; Ciro Abbondanza; Joost Martens; Matthias Nees; Rosaria Benedetti; Isabella Pallavicini; Saverio Minucci; Guillermo Garcia-Manero; Francesco Iovino; Gabriella Lania; Concetta Ingenito; Valeria Belsito Petrizzi; Hendrik G Stunnenberg; Lucia Altucci
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

Review 3.  Sirtuin Inhibition: Strategies, Inhibitors, and Therapeutic Potential.

Authors:  Yanhong Jiang; Jiajia Liu; Di Chen; Lingling Yan; Weiping Zheng
Journal:  Trends Pharmacol Sci       Date:  2017-04-05       Impact factor: 14.819

4.  BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.

Authors:  S L Locatelli; L Cleris; G G Stirparo; S Tartari; E Saba; M Pierdominici; W Malorni; A Carbone; A Anichini; C Carlo-Stella
Journal:  Leukemia       Date:  2014-02-24       Impact factor: 11.528

Review 5.  Roles of reactive oxygen species in cell signaling pathways and immune responses to viral infections.

Authors:  Zhenguang Li; Xiaoqin Xu; Xue Leng; Minghui He; Jiangke Wang; Shipeng Cheng; Hua Wu
Journal:  Arch Virol       Date:  2016-11-15       Impact factor: 2.574

6.  HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Authors:  Tri Nguyen; Yun Dai; Elisa Attkisson; Lora Kramer; Nicholas Jordan; Nguyen Nguyen; Nikhil Kolluri; Markus Muschen; Steven Grant
Journal:  Clin Cancer Res       Date:  2011-04-07       Impact factor: 12.531

7.  A phosphorylation-acetylation switch regulates STAT1 signaling.

Authors:  Oliver H Krämer; Shirley K Knauer; Georg Greiner; Enrico Jandt; Sigrid Reichardt; Karl-Heinz Gührs; Roland H Stauber; Frank D Böhmer; Thorsten Heinzel
Journal:  Genes Dev       Date:  2009-01-15       Impact factor: 11.361

Review 8.  HDAC inhibitors: roles of DNA damage and repair.

Authors:  Carine Robert; Feyruz V Rassool
Journal:  Adv Cancer Res       Date:  2012       Impact factor: 6.242

9.  The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells.

Authors:  Kathryn Clarke; Christine Young; Fabio Liberante; Mary-Frances McMullin; Alexander Thompson; Ken Mills
Journal:  Oncotarget       Date:  2019-05-28

Review 10.  ROS in cancer therapy: the bright side of the moon.

Authors:  Bruno Perillo; Marzia Di Donato; Antonio Pezone; Erika Di Zazzo; Pia Giovannelli; Giovanni Galasso; Gabriella Castoria; Antimo Migliaccio
Journal:  Exp Mol Med       Date:  2020-02-14       Impact factor: 8.718
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.